Last reviewed · How we verify

Indomethacin 0.5% eyedrops

Università degli Studi di Brescia · Phase 3 active Small molecule

Indomethacin 0.5% eyedrops is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Università degli Studi di Brescia. It is currently in Phase 3 development for Postoperative ocular inflammation and pain following cataract surgery, Seasonal allergic conjunctivitis, Corneal refractive surgery-related inflammation.

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative ocular inflammation and pain following cataract surgery, Seasonal allergic conjunctivitis, Corneal refractive surgery-related inflammation.

At a glance

Generic nameIndomethacin 0.5% eyedrops
SponsorUniversità degli Studi di Brescia
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase (COX-1, COX-2)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

As a topical NSAID eyedrop, indomethacin blocks COX-1 and COX-2 enzymes, thereby decreasing production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and potentially other prostaglandin-mediated effects in the anterior segment of the eye. The 0.5% formulation delivers the drug directly to ocular tissues with minimal systemic absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Indomethacin 0.5% eyedrops

What is Indomethacin 0.5% eyedrops?

Indomethacin 0.5% eyedrops is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Università degli Studi di Brescia, indicated for Postoperative ocular inflammation and pain following cataract surgery, Seasonal allergic conjunctivitis, Corneal refractive surgery-related inflammation.

How does Indomethacin 0.5% eyedrops work?

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

What is Indomethacin 0.5% eyedrops used for?

Indomethacin 0.5% eyedrops is indicated for Postoperative ocular inflammation and pain following cataract surgery, Seasonal allergic conjunctivitis, Corneal refractive surgery-related inflammation.

Who makes Indomethacin 0.5% eyedrops?

Indomethacin 0.5% eyedrops is developed by Università degli Studi di Brescia (see full Università degli Studi di Brescia pipeline at /company/universit-degli-studi-di-brescia).

What drug class is Indomethacin 0.5% eyedrops in?

Indomethacin 0.5% eyedrops belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is Indomethacin 0.5% eyedrops in?

Indomethacin 0.5% eyedrops is in Phase 3.

What are the side effects of Indomethacin 0.5% eyedrops?

Common side effects of Indomethacin 0.5% eyedrops include Ocular irritation or stinging, Conjunctival hyperemia, Corneal erosion or keratitis, Headache.

What does Indomethacin 0.5% eyedrops target?

Indomethacin 0.5% eyedrops targets Cyclooxygenase (COX-1, COX-2) and is a Nonsteroidal anti-inflammatory drug (NSAID).

Related